血必凈注射液聯(lián)合烏司他丁注射液治療重癥膿毒癥休克患者的臨床研究
發(fā)布時間:2018-11-22 11:53
【摘要】:目的觀察血必凈注射液聯(lián)合烏司他丁注射液治療重癥膿毒癥休克的臨床療效及安全性。方法將68例重癥膿毒癥休克患者隨機分為對照組34例和試驗組34例。對照組予以靜脈滴注血必凈50 mL,bid;試驗組在對照組治療的基礎上,聯(lián)合靜脈滴注烏司他丁60萬U,bid。2組患者均治療2周。比較2組患者的臨床療效、臨床指標、生化指標、死亡率及藥物不良反應的發(fā)生情況。結(jié)果治療后,試驗組和對照組的總有效率分別為91.18%(31/34例)和88.24%(30/34例),差異無統(tǒng)計學意義(P0.05)。治療后,試驗組和對照組的C反應蛋白分別為(24.56±4.21)和(48.21±5.22)mg·L~(-1),降鈣素原分別為(1.04±0.21)和(2.88±0.45)ng·mL~(-1),白細胞分別為(8.75±2.12)×109和(13.48±3.45)×109/L,腦鈉肽分別為(0.54±0.05)和(0.87±0.15)ng·mL~(-1),肌鈣蛋白T分別為(0.35±0.03)和(0.76±0.18)ng·mL~(-1),肌鈣蛋白Ⅰ分別為(0.42±0.07)和(0.87±0.24)ng·mL~(-1),肌酸激酶同工酶分別為(14.57±2.41)和(18.79±3.52)U·L~(-1),乳酸分別為(2.65±0.46)和(5.21±1.04)nmol·L~(-1),機械通氣時間分別為(10.21±1.56)和(18.22±3.87)d,住院時間分別為(16.09±2.45)和(24.33±4.53)d,差異均有統(tǒng)計學意義(均P0.05)。試驗組和對照組各發(fā)生皮疹1例,差異無統(tǒng)計學意義(P0.05)。試驗組和對照組的死亡率分別為5.88%和26.47%,差異有統(tǒng)計學意義(P0.05)。結(jié)論血必凈注射液聯(lián)合烏司他丁注射液治療重癥膿毒癥休克的臨床療效與單用血必凈注射液相當,但前者能明顯改善患者的生化指標,縮短住院時間,降低死亡率,且不增加藥物不良反應發(fā)生率。
[Abstract]:Objective to observe the efficacy and safety of Xuebijing injection combined with ulinastatin injection in the treatment of severe septic shock. Methods 68 patients with severe septic shock were randomly divided into control group (n = 34) and experimental group (n = 34). The patients in the control group were treated with intravenous drip of Xuebijing 50 mL,bid; on the basis of the control group, and the patients in the control group were treated with ulinastatin 600000 Ubid.2 intravenous drip for 2 weeks. The clinical efficacy, clinical indexes, biochemical indexes, mortality and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 91.18% (31 / 34 cases) and 88.24% (30 / 34 cases), respectively. The difference was not statistically significant (P0.05). After treatment, C-reactive protein and procalcitonin were (24.56 鹵4.21) and (48.21 鹵5.22) mg L ~ (-1), (1.04 鹵0.21) and (2.88 鹵0.45) ng mL~ (-1), respectively. WBC were (8.75 鹵2.12) 脳 109 and (13.48 鹵3.45) 脳 109 / L, brain natriuretic peptide were (0.54 鹵0. 05) and (0. 87 鹵0. 15) ng mL~ (-1), respectively. Troponin T was (0.35 鹵0.03) and (0.76 鹵0.18) ng mL~ (-1), troponin 鈪,
本文編號:2349301
[Abstract]:Objective to observe the efficacy and safety of Xuebijing injection combined with ulinastatin injection in the treatment of severe septic shock. Methods 68 patients with severe septic shock were randomly divided into control group (n = 34) and experimental group (n = 34). The patients in the control group were treated with intravenous drip of Xuebijing 50 mL,bid; on the basis of the control group, and the patients in the control group were treated with ulinastatin 600000 Ubid.2 intravenous drip for 2 weeks. The clinical efficacy, clinical indexes, biochemical indexes, mortality and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 91.18% (31 / 34 cases) and 88.24% (30 / 34 cases), respectively. The difference was not statistically significant (P0.05). After treatment, C-reactive protein and procalcitonin were (24.56 鹵4.21) and (48.21 鹵5.22) mg L ~ (-1), (1.04 鹵0.21) and (2.88 鹵0.45) ng mL~ (-1), respectively. WBC were (8.75 鹵2.12) 脳 109 and (13.48 鹵3.45) 脳 109 / L, brain natriuretic peptide were (0.54 鹵0. 05) and (0. 87 鹵0. 15) ng mL~ (-1), respectively. Troponin T was (0.35 鹵0.03) and (0.76 鹵0.18) ng mL~ (-1), troponin 鈪,
本文編號:2349301
本文鏈接:http://sikaile.net/linchuangyixuelunwen/2349301.html
最近更新
教材專著